Exabis Library:

Welcome to the e-CCO Library!

Search by:

All Congress AbstractsCongress SlidesTools & SkillsVideos & Podcasts

Year: Category:

DOP37: Noninvasive assessment of gut function using transcriptional recording sentinel cells

Year: 2024

Source: ECCO'24 Stockholm

Authors: Zimmermann, Jakob

Created: Tuesday, 30 April 2024, 5:03 PM

DOP37: Vedolizumab-induced endoscopic remission in anti-TNF exposed and anti-TNF naïve IBD patients: a large single-centre experience

Year: 2019

Source:

ECCO '19 Copenhagen

Authors:

B. Verstockt*^1,2, E. Mertens¹, A. Outtier¹, G. Van Assche^1,2, S. Vermeire^1,2, M. Ferrante^1,2

Created: Friday, 22 February 2019, 9:41 AM

DOP37: Vedolizumab-induced endoscopic remission in anti-TNF exposed and anti-TNF naïve IBD patients: a large single centre experience

Year: 2019

Source: ECCO'19 Copenhagen

Authors: Bram Verstockt

Created: Tuesday, 28 May 2019, 3:32 PM

colonoscopy, Mucosal healing, Vedolizumab, Mucosal healing, Real world data, Mucosal healing

Files: 1

DOP38 Prevalence of fatigue in a severe inflammatory bowel disease cohort highly exposed to biologics

Year: 2020

Source:

ECCO'20 Vienna

Authors:

C. Liefferinckx^1,2, M. El hamdi¹, M. Fassin², A. Cremer^1,2, C. Minsart^1,2, L. Amininejad¹, V. Wambacq¹, A. Van Gossum¹, D. Franchimont^1,2

Created: Thursday, 30 January 2020, 10:12 AM

DOP38: A rare KRT17+ population emerges from the epithelium in the inflamed intestinal mucosa of patients with Ulcerative Colitis

Year: 2024

Source: ECCO'24 Stockholm

Authors: Dotti, Isabella

Created: Tuesday, 30 April 2024, 5:03 PM

DOP38: A vedolizumab specific four-gene colonic signature accurately predicting future endoscopic remission in patients with inflammatory bowel disease

Year: 2019

Source: ECCO'19 Copenhagen

Authors: Bram Verstockt

Created: Tuesday, 28 May 2019, 3:32 PM

Mucosal healing, Prognosis, Anti-TNF agents, Vedolizumab

Files: 1

DOP38: A vedolizumab specific four-gene colonic signature accurately predicting future endoscopic remission in patients with inflammatory bowel disease

Year: 2019

Source:

ECCO '19 Copenhagen

Authors:

B. Verstockt*^1,2, S. Verstockt³, P. Sudahakar^2,4,5, J. Dehairs⁶, H. Blevi², G. Van Assche^1,2, S. Vermeire^1,2, M. Ferrante^1,2

Created: Friday, 22 February 2019, 9:41 AM

DOP38: An observational study to evaluate the burden of illness in patients with Crohn’s Disease with and without perianal fistulas in the USA

Year: 2021

Source: ECCO'21 Virtual

Authors: Jiang, J.(1);Cazzetta, S.E.(2);Athavale, A.(3);Kuharic, M.(1,4);Fan, T.(1);Silber, A.(5);Vijay, A.(3);Hadker, N.(5);Sharpe, E.(5);Nazarey, P.P.(2)

Created: Wednesday, 2 June 2021, 4:12 PM

DOP38: Prevalence of fatigue in a severe Inflammatory Bowel Disease cohort highly exposed to biologics

Year: 2020

Source: ECCO'20 Vienna

Authors: Claire Liefferinckx

Created: Tuesday, 23 June 2020, 5:40 PM

DOP38: Prevalence of fatigue in a severe Inflammatory Bowel Disease cohort highly exposed to biologics

Year: 2020

Source: ECCO'20 Vienna

Authors: Claire Liefferinckx

Created: Tuesday, 23 June 2020, 4:58 PM

Files: 1

DOP38: Upadacitinib Therapy Reduces Crohn's Disease Symptoms Within the First Week of Induction Therapy

Year: 2023

Source: ECCO’23 Copenhagen

Authors: Colombel, J.F.(1)*;Hisamatsu, T.(2);Bresso , F.(3);Thin, L.(4);Parra, R.(5);Ford, S.(6);Remple, V.(6);Lacerda, A.P.(6);Hecht, P.(6);Mallick, M.(6);Garrison, A.(6);Regueiro, M.(7);

Created: Friday, 14 July 2023, 10:43 AM

DOP38: Upadacitinib Therapy Reduces Crohn’s Disease Symptoms Within the First Week of Induction Therapy

Year: 2023

Source: ECCO’23 Copenhagen

Authors: Jean-Frédéric Colombel

Created: Friday, 14 July 2023, 2:22 PM

DOP38: Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1

Year: 2022

Source: ECCO'22

Authors: Vermeire, S.(1);Colombel, J.F.(2);Takeuchi, K.(3);Gao, X.(4);Panaccione, R.(5);Danese, S.(6);Dubinsky, M.(7);Schreiber, S.(8);Ilo, D.(9);Finney-Hayward, T.(9);Zhou, W.(9);Phillips, C.(9);Yao, X.(9);Zhou, Q.(9);Loftus, E.(10);

Created: Friday, 11 February 2022, 3:52 PM

DOP39 The first prospective, multicentre, randomised controlled trial on discontinuation of infliximab in ulcerative colitis in remission; endoscopic normalisation does not guarantee successful withdrawal

Year: 2020

Source:

ECCO'20 Vienna

Authors:

T. Kobayashi¹, S. Motoya², S. Nakamura³, T. Yamamoto⁴, M. Nagahori⁵, S. Tanaka⁶, T. Hisamatsu⁷, F. Hirai⁸, H. Nakase⁹, K. Watanabe¹⁰, T. Matsumoto¹¹, M. Tanaka¹², T. Abe¹³, Y. Suzuki¹⁴, M. Watanabe⁵, T. Hibi¹, HAYABUSA

Created: Thursday, 30 January 2020, 10:12 AM

DOP39: Constructing butyrate-producing yeast as a cell-dependent treatment option for Inflammatory Bowel Disease

Year: 2024

Source: ECCO'24 Stockholm

Authors: Wu, Jiahao

Created: Tuesday, 30 April 2024, 5:03 PM

DOP39: Effect of baseline disease characteristics on clinical outcomes in moderate-to-severe Ulcerative Colitis treated with upadacitinib: Results from a Phase 3 trials programme

Year: 2022

Source: ECCO'22

Authors: Higgins, P.(1);Colombel, J.F.(2);Reguiero, M.(3);Parkes, G.(4);Ilo, D.(5);Philips, C.(5);Yao, X.(6);Cheng, E.(6);Schreiber, S.(7);

Created: Friday, 11 February 2022, 3:52 PM

DOP39: Endoscopic, histologic, and combined outcomes with reinitiation of ozanimod after temporary discontinuation: 2-year interim analysis of the True North open-label extension study

Year: 2023

Source: ECCO’23 Copenhagen

Authors: Séverine Vermeire

Created: Friday, 14 July 2023, 2:22 PM

DOP39: Endoscopic, histologic, and combined outcomes with reinitiation of ozanimod after temporary discontinuation: 2-year interim analysis of the True North open-label extension study

Year: 2023

Source: ECCO’23 Copenhagen

Authors: Vermeire, S.(1)*;Dignass, A.(2);Colombel, J.F.(3);Jain, A.(4);Canavan, J.B.(4);Wu, H.(4);Lawlor, G.(4);Osterman, M.T.(4);Rubin, D.T.(5);Regueiro, M.(6);

Created: Friday, 14 July 2023, 10:43 AM

DOP39: Safety of Combination Biologic and Anti-Rejection Therapy Post-Liver Transplantation in Patients with Inflammatory Bowel Disease: London Ontario Experience

Year: 2019

Source: ECCO'19 Copenhagen

Authors: Christopher Ma

Created: Tuesday, 28 May 2019, 3:32 PM

Adalimumab, Anti-TNF agents, Golimumab, Infliximab, Ustekinumab, Vedolizumab, Sclerosing Cholangitis, IBD-associated cancer, Clostridium difficile, Colorectal cancer, CMV, IBD and malignancy, Mortality, Real world data, Patient reported outcomes

Files: 1

DOP39: Safety of combination biologic and anti-rejection therapy post-liver transplantation in patients with inflammatory bowel disease: London Ontario experience

Year: 2019

Source:

ECCO '19 Copenhagen

Authors:

S. Al Draiweesh*^1,2, C. Ma^1,3, M. Alkhattabi¹, N. Chande¹, B. G. Feagan¹, J. C. Gregor¹, R. Khanna¹, P. Marotta¹, A. Sandhu¹, K. Qumosani¹, A. Teriaky¹, M. Brahmania¹, V. Jairath^1,4,5

Created: Friday, 22 February 2019, 9:41 AM